Drug ‘breakthrough’ gives longest-ever survival in non-resectable liver cancer patients
The IMbrave150 trial found median overall survival was 19.2 months in patients treated with atezo…
Browsing: sorafenib
New data on emerging treatments for liver cancer raise hope for advanced disease patients
New treatment options for people with advanced or unresectable hepatocellular carcinoma (HCC) may now be…
A new treatment for liver cancer
In the journal Molecular Therapy, Skoltech and MIT researchers have published a new combinatorial therapy for…
SIRT better tolerated than sorafenib, but doesn’t increase overall survival in HCC
Results of the SARAH trial presented today demonstrate that SIRT resulted in median overall survival…